Biotechnology Analysts Agrawal and Kluska review the key insights from NASH Physician, discuss investor feedback/pushback on recent Akero initiation, discuss latest sentiment on 89bio and how Akero’s data may read into this stock on an Analyst/Industry conference call to be held on September 29 at 12 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AKRO:
- Biotech Alert: Searches spiking for these stocks today
- 3 Best Stocks to Buy Now, 9/26/2023, According to Top Analysts
- 3 Best Stocks to Buy Now, 9/19/2023, According to Top Analysts
- Akero Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Akero Therapeutics price target raised to $60 from $50 at Evercore ISI